Equity capital markets

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Retrieved on: 
Tuesday, February 13, 2024
Attention, Jefferies Group, Prospectus, Telephone, Cardiovascular disease, RBC Capital Markets, Sale, Equity capital markets, Form, Nicollet Mall, Risk, NAMS, State Street, SVB Securities, Madison Avenue, Patient, Common stock, Vesey Street

NAARDEN, The Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of the Company’s ordinary shares, with a nominal value of €0.12 per share (“Ordinary Shares,”) and, to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase Ordinary Shares (“Pre-Funded Warrants,” such offering, the “Offering”).

Key Points: 
  • NAARDEN, The Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of the Company’s ordinary shares, with a nominal value of €0.12 per share (“Ordinary Shares,”) and, to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase Ordinary Shares (“Pre-Funded Warrants,” such offering, the “Offering”).
  • All Ordinary Shares and Pre-Funded Warrants to be sold in the proposed Offering will be sold by the Company.
  • In addition, the Company expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exceed 15% of the securities sold in the proposed Offering.
  • Jefferies, Leerink Partners, Piper Sandler, and RBC Capital Markets are acting as joint book-running managers for the proposed Offering.

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

Retrieved on: 
Friday, February 9, 2024
Equity capital markets, Suite, Sale, Form, Metoclopramide, Security (finance), Attention, Fifth Avenue, Capital Group Companies, Evoke, Telephone, Series

The combined price per share of common stock, Series A Warrant, Series B Warrant and Series C Warrant is $0.68, totaling $7.5 million initial gross proceeds to the Company.

Key Points: 
  • The combined price per share of common stock, Series A Warrant, Series B Warrant and Series C Warrant is $0.68, totaling $7.5 million initial gross proceeds to the Company.
  • If the Series A Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • If the Series B Warrants are exercised in full, the Company would receive an additional $7.5 million in gross proceeds.
  • Evoke intends to use the net proceeds from the public offering for working capital and general corporate purposes.

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock

Retrieved on: 
Tuesday, February 6, 2024
Security (finance), CD117, RBC, Telephone, Syndrome, Equity capital markets, Capital market, Public expenditure, Attention, Prospectus, Lexington Avenue, MDS, CSU, Therapy, Risk, RBC Capital Markets, Evercore, Sale, Jasper, Form

Each share of common stock will be sold at an offering price of $12.95 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • Each share of common stock will be sold at an offering price of $12.95 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses.
  • All of the shares of common stock are being offered by Jasper.
  • The offering is expected to close on or about February 8, 2024, subject to the satisfaction of customary closing conditions.
  • A prospectus supplement and the accompanying prospectus relating to and describing the offering has been filed with the SEC.

Stifel Named US Mid-Market Equity House of the Year by International Financing Review

Retrieved on: 
Monday, February 5, 2024
Cava (restaurant), Eaton Partners, SF, Research, International, International Financing Review, News, House, Equity capital markets, Fintech, Initial public offering, IPO, Bookrunner, KBW, Therapy, Broker-dealer, Natural Resources, Insurance, Security (finance)

ST. LOUIS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced it has been named 2023 US Mid-Market Equity House of the Year by International Financing Review (IFR), recognizing outstanding capital markets achievement.

Key Points: 
  • ST. LOUIS, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced it has been named 2023 US Mid-Market Equity House of the Year by International Financing Review (IFR), recognizing outstanding capital markets achievement.
  • Stifel served as bookrunner on several high-profile transactions across multiple sectors, including the IPOs of Mach Natural Resources, Neumora Therapeutics and Cava Group.
  • “The market is unbelievably competitive for the dollars that are out there,” said Seth Rubin, Head of US Equity Capital Markets at Stifel.
  • Stifel was previously named U.S. Mid-Market Equity House of the Year in 2021.

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, February 2, 2024
Security (finance), SAN, Bank of America, Genetically modified bacteria, SVB Securities, Madison Avenue, Telephone, Guggenheim Partners, Exercise, Equity capital markets, Cantor, Attention, Prospectus, BofA Securities, Jefferies Group, Evercore, Sale, Needham & Company, State Street

This includes the exercise in full by the underwriters of their option to purchase up to 1,757,812 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions.

Key Points: 
  • This includes the exercise in full by the underwriters of their option to purchase up to 1,757,812 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions.
  • The aggregate gross proceeds to Vaxcyte from this offering were approximately $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
  • BofA Securities, Jefferies, Leerink Partners LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint book-running managers for the offering.
  • BTIG and Needham & Company acted as lead managers for the offering.

Fractyl Health Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, February 2, 2024
T2D, Obesity, Therapy, Varick Street, Equity capital markets, Attention, Prospectus, BofA Securities, 2nd Floor, Morgan Stanley, Evercore, Sale, Cryptocurrency

LEXINGTON, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, today announced the pricing of its initial public offering of 7,333,333 shares of common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $110.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Fractyl Health.

Key Points: 
  • LEXINGTON, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, today announced the pricing of its initial public offering of 7,333,333 shares of common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $110.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Fractyl Health.
  • All of the common stock is being offered by Fractyl Health.
  • The offering is expected to close on February 6, 2024, subject to customary closing conditions.
  • In addition, Fractyl Health has granted the underwriters a 30-day option to purchase up to an additional 1,099,999 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Retrieved on: 
Thursday, February 1, 2024
Security (finance), Form S-3, Telephone, Exercise, Equity capital markets, Patient, Attention, Prospectus, Lexington Avenue, Broadridge Financial Solutions, Therapy, Evercore, Sale, Form

The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and offering expenses, are approximately $287.5 million.

Key Points: 
  • The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and offering expenses, are approximately $287.5 million.
  • J.P. Morgan, TD Cowen and Evercore ISI acted as joint book-running managers for the offering.
  • A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available for free on the SEC’s website located at http://www.sec.gov.
  • A final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available for free on the SEC’s website located at http://www.sec.gov.

Vaxcyte Announces Pricing of $750 Million Public Offering

Retrieved on: 
Wednesday, January 31, 2024
Security (finance), SAN, Bank of America, Genetically modified bacteria, SVB Securities, Madison Avenue, Telephone, Guggenheim Partners, Exercise, Equity capital markets, Cantor, Attention, Prospectus, BofA Securities, Jefferies Group, Evercore, Sale, Needham & Company, State Street

Vaxcyte is selling 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock in the offering.

Key Points: 
  • Vaxcyte is selling 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock in the offering.
  • The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant.
  • The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $750.0 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants.
  • All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Tuesday, January 30, 2024
Security (finance), SAN, Bank of America, Genetically modified bacteria, SVB Securities, Madison Avenue, Telephone, Guggenheim Partners, Equity capital markets, Cantor, Attention, Prospectus, BofA Securities, Jefferies Group, Evercore, Sale, Needham & Company, State Street

All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.

Key Points: 
  • All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte.
  • Vaxcyte intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering (including shares underlying the pre-funded warrants).
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • BofA Securities, Jefferies, Leerink Partners, Evercore ISI, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering.

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Retrieved on: 
Tuesday, January 30, 2024
Security (finance), Form S-3, Telephone, Equity capital markets, Patient, Attention, Prospectus, Lexington Avenue, Broadridge Financial Solutions, Therapy, Evercore, Sale, Form

BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an upsized underwritten public offering of 8,064,517 shares of its Class A common stock at a price to the public of $31.00 per share.

Key Points: 
  • BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an upsized underwritten public offering of 8,064,517 shares of its Class A common stock at a price to the public of $31.00 per share.
  • The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $250.0 million.
  • In addition, Vera has granted the underwriters a 30-day option to purchase up to an additional 1,209,677 shares of Class A common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on February 1, 2024, subject to the satisfaction of customary closing conditions.